The engines have fired up at last for MDX. ( BPRG ) At long last they are being recognised for the force they will become over the next two years. On the cusp of disclosing huge revenue-earning deals with Global pharmacists. These have been hinted at as being unrolled before the years end, but may be in the next days.You still have time to get in at a bargain-basement price before the SP takes off for real shortly.

I prefer not to be asked

lol

... you starting to sound like Barry.

I cant believe the postings on the adv.. Mdx threadit makes you wonder how much you can fraudulently steal from investorshow blatant you can perform this actand how uninterested the authorities areits all their bar the handcuffsand the fcuking idiots that uphold the lawcouldnt uphold their dicks sod working for a livingthe authorities with all this information are a disgrace..


Meldex International
Trading Update

Meldex International PLC
24 January 2008



24 January 2008

Meldex International plc

Meldex reports strong trading and operational progress in pre close update

London, UK, 24 January 2008, Meldex International plc ('Meldex', the 'Company'
or the 'Group') (AIM:MDX), the specialty pharmaceutical and healthcare company,
announces strong trading for the year ended 31 December 2007 ahead of the close
period preceding publication of the Group's preliminary results, planned for
announcement during April 2008.

Key Highlights:

Revenue growth of 217 per cent. from 9.5 million in 2006 to 30 million
in 2007 at the top end of equity analyst expectations

Integration of all acquisitions completed; demonstrated by cross
fertilisation of regional products, enhanced distribution partnering
arrangements and successful product launches throughout the Group

Transformational acquisition of the Melbrosin group of companies has
rapidly created a global OTC division

Significant enhancement of portfolio through selective product
acquisitions such as the antacid RocgelTM and antibiotic Alfatil

TabWrapTM, Solupol, Meltums and SoluleavesTM commercial launches

Launch of high growth products including the analgesics range and
nicotine replacement therapy in both prescription and OTC markets
exhibiting early signs of good growth potential

Trading to date in 2008 has been strong


Richard Trevillion, Chief Executive, said:

'Meldex has had a superb trading year in 2007. The Group has out-performed its
own targets and has demonstrated robust and rapid organic growth. The Company's
pipeline and growing portfolio of products provide a strong platform for further
growth in 2008 and beyond.

Key launches of products such as analgesics and the nicotine replacement strip,
benefitting from TabWrapTM, SoluleavesTM and Solupol enabling technologies, have
been successfully achieved. We are excited by our newly acquired brands Rocgel
and Alfatil, our extended analgesic range and other key product developments.
This means that Meldex is well positioned going forward.'

For further information:

Meldex International plc + 44 (0)20 7098 9880
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Corfin Communications + 44 (0)20 7977 0020
Martin Sutton

About Meldex International plc

Meldex International plc is an innovative specialty pharmaceutical and Over The
Counter ('OTC') product company. Listed on London's AIM in May 2003, the Company
has over 80 patents granted or in business within 24 patent families and has
product development agreements and strategic alliances with several global
healthcare companies.

Meldex has acquired sales and marketing resources within Europe and the US as a
launch mechanism for its own pharmaceutical products. Meldex acquired the
Melbrosin business in June 2007 for a consideration of up to 35 million.
Melbrosin's focus is on consumer OTC healthcare products based on substances of
natural and plant origin which are developed into consumer orientated brands
then scaled, produced and distributed by Melbrosin. Melbrosin complements the
prescription pharmaceutical sales and marketing business created and expanded in
2006.

The business continues to develop innovative delivery mechanisms enhancing both
its own product range and those of selected partners using its proprietary
XGELTM polymer technology.

For further information please go to www.meldexinternational.com




This information is provided by RNS
The company news service from the London Stock Exchange

---------------------------------------------------------
B J Muncaster - 24 Sep'10 - 13:37 - 16695 of 16713

RT was CEO.

SM was CDO.

RT and SM were tied at the hip.

HP was FD under the control of RT and SM.

JC worked for HP.

Now, for those who think that down-the-line JC or for that matter any manager knew what was going on, go through this little beauty, and there's a lot more like it:

----- Original Message -----
From: Paul F. KENNEDY
To: Steve Martin
Sent: Wed Apr 30 14:14:46 2008
Subject: Invoice for 50,000 Euros.

Steve,

Can you please arrange payment by return.

Thanks.

Paul

Tel 06 09 82 44 13

De : Steve Martin [mailto:Steve.Martin@meldexinternational.com]
Envoy: mercredi 30 avril 2008 15:18
: paulfkennedy@yahoo.co.uk
Cc : richard.trevillion@btopenworld.com
Objet : Re: Invoice for 50,000 Euros.

Paul

I have forwarded this over to Richard who will sort this out.

Regards

Steve

----- Original Message -----
From: Paul F. KENNEDY
To: Steve Martin
Cc: Richard bt
Sent: Wed Apr 30 14:49:19 2008
Subject: RE: Invoice for 50,000 Euros.

Steve,

Thanks.

Given the situation I would obviously appreciate prompt payment.

Regards,

Paul

Tel 06 09 82 44 13
De : Steve Martin [mailto:Steve.Martin@meldexinternational.com]
Envoy: mercredi 30 avril 2008 15:51
: paulfkennedy@yahoo.co.uk
Objet : Re: Invoice for 50,000 Euros.

It will be sorted. We have to sneak it under Hirals radar screen!!!!!!!

Steve
----- Original Message -----
From: Paul F. KENNEDY
To: Steve Martin
Sent: Wed Apr 30 15:00:40 2008
Subject: RE: Invoice for 50,000 Euros.

But presumably Dexo France will need to pay ?

Regards,

Paul

Tel 06 09 82 44 13

De : Steve Martin [mailto:Steve.Martin@meldexinternational.com]
Envoy: mercredi 30 avril 2008 16:05
: paulfkennedy@yahoo.co.uk
Objet : Re: Invoice for 50,000 Euros.

Yes, but HP looks at every invoice so we have to sneak it under the radar screen!!! Just have to play a little game (which should be unnecessary) here. Fear not!

----- Original Message -----
From: Paul F. KENNEDY
To: Steve Martin
Sent: Wed Apr 30 15:09:28 2008
Subject: RE: Invoice for 50,000 Euros.

I trust you.

Try to get it done by next week.

Is the rest ok?

When are you in Paris?

Regards,

Paul

Tel 06 09 82 44 13

-----Original Message-----
From: Steve Martin
Sent: 30 April 2008 15:15
To: 'paulfkennedy@yahoo.co.uk'
Subject: Re: Invoice for 50,000 Euros.

I will do what I can!

I have been in Paris today and on train back. It looked as if I was having 3 or 4 hours spare but I needed to get back with my team. I have some urgent work re the bids etc to get done tonight!!!!

Otherwise it would have been meeting at Gare du Nord in a bar!!!! You would have met Chris Mugglestone my colleague!

I will try and call this evening!

Steve

All been at it from day one tabby and imo still are.

How much pocket money do you think Stevie Baby had put by for the offer?did he run it under Hirals radar screenwas it a lead 1? why wasnt it excepted?


Thursday 17 July, 2008
Meldex International
Potential Offer
RNS Number : 2589Z
Meldex International PLC
17 July 2008




For Immediate Release 17 July 2008


Meldex International plc


Potential Offer


London, UK: Meldex International plc ('the Company'), the specialty pharmaceutical and healthcare company, announces that Steve Martin, the Chief Development Officer and Board member of the Company, has made an approach to the Board of Directors ('the Board') seeking permission to explore the possibility of making an offer for the Company.


There can be no guarantee that this approach will lead to an offer being made for the issued ordinary share capital of the Company, or that any transaction will be recommended by the Board or consummated.


An Independent Committee of the Board has been formed for the purposes of considering any and all offers made. A further announcement will be made in due course.

I wonder who was shorting at this timetuff one?

Everyone who could read a chart ?

B J Muncaster - 26 Sep'10 - 10:00 - 17119 of 17189

You've already had it. In any event do you really think anything I say would put an end to conspiracy theories? What could I possibly do or say to stop such silly things as failed investor thinking birotop is my son? Or others who already think the assets have been sold, when they haven't? Or those who think the vote to stop the 100 million share authorisation was all part of a master plan?

Don't you think it a little odd than nobody, specifically the naysayers, seems interested in Inghu's insider dealing ring? Or SM and his mate Kennedy (Dagmar/Winford/D&A Pharma) keeping invoices under the FD's radar? Or RT allegedly transferring all his assets to his wife on Xmas eve 2007 at the end of a quarter that saw a string of false RNSs? Or a CEO who claims the Company had been defrauded of 20M but didn't think it ncessary to bring the matter to the attention of the Company's lawyers, or board, or auditors, or NOMAD, or the police, until a few days after he was relieved of duties? Or SM, who as a board member signed off 2008 interims that included 12M of false deals, of which 4M relates to a deal that SM, via his lawyers, now seems to recall "didn't happen"? Or the whole board signing off accounts that included deals with Dagmar, when we have a letter from Dagmar's (Kennedey's) lawyers saying the deals didn't happen. Or how Al-doori is refusing to hand over documents relating to transactions with Crescent which a forensic investigation concluded didn't happen. Or banking covenents being broken in March/April 2008 but not announced to the market? Or SM in emails to the board claiming RT forced him to lie to the FD about a deal with ICE Pharma? I could go on and on.

Or would focus on these issues not suit the agendas of the naysayers?
..............................

Dildont get me wrongbut I think Barrys explanation is slightly better than your fcuking chart crap!.btw just watched a crap F1 ...makes reading some of these posts quite interesting.

Part of another BM post...

B J Muncaster - 26 Sep'10 - 10:20 - 17126 of 17195

arab3,

"That's not the lot by a long chalk! We didn't lose the case, we were unable to continue it because of lack of funds. If for one minute RT and SM think this is over they'll soon find out they're living in lala land."

Wish someone had emailed me.

... and if you think Barry is whiter than white then you too are living in lala land.

I gave him two examples of where he had lied when he asked me tabby but he still didn't come back and answer my questions ... you forgot to copy that on here !

Personally i just consider myself a chartist. as in, read the charts.or at least try to. sometimes i am right and sometimes i am wrong. so why do i bother? mostly because i find it offers me a degree of protection from that which is said and reported and that which actually is. as is being what is actually going on "behind the scene" or should that be screen?
if that "lost" invoice had not got paid, which i dont know if it did or not. does anyone? if so please advise and confirm.and if it hadn't, been paid that is, then lack of funds may not have proven a problem. this can easily be verified by a simple statement. i.e. yes it did get paid ,or no it didn't get paid. who is best positioned to make such a statement?
so lets hear it.
anyway as a none shareholder i suppose i will be informed that it is none of my concern or business. thats fair enough. maybe someone who is a shareholder might like to ask the question? in the mean time the saga continues.
regards
jkd

Very interesting? >

mad mike - 26 Sep'10 - 23:41 - 17310 of 17314

scottie, a technical correction to your post #17308.

There are circumstance where it is unnecessary to gain access to an individuals's account statements to prove trading has occurred (& thus possibly insider trading).

You would need account access for many (but not all) nominee accounts, CfDs and spreadbets.

However, you don't need such access with certificated shares, or CREST accounts where you already know who controls the CREST account (even if it is classed as a nominee account). In these cases, all you need is access to a company's full transaction share register. A company has such access to its own transaction share register, though most companies don't seem to realise it.

As explained in my much earlier visit report to HQ, following a fair amount of investigation, I worked out how Meldex management could get a copy of Meldex's full transaction share register. Thanks to Barry, I have a copy i.e. a three year full transaction share register. Of course Barry also has a copy.

FYI, a full transaction share register records every single share transaction in a company's shares (matched buy & sell between named accounts), whether on or off market, plus all new share issues, and any share cancellations.

jkd - 26 Sep 2010 20:56 - 8573 of 8574
Personally i just consider myself a chartist.
----------------------------
No!..you are much more than that my little peeps?.lol

cambridge-news.co.uk

Published: 28/09/2010 09:23 - Updated: 28/09/2010 09:27
Meldex losses total 74m as administrators go in
Former AIM-listed Meldex International, previously known as BioProgress and based on Cambridge Science Park, has gone into administration with losses of 74m.

The administrators are working with the directors to sell the firms main trading subsidiary, BioProgress Technology, as a going concern and its business is unaffected.
Chris McKay, of administrators McTear Williams & Wood, said: The companys recent past has not been pretty. Its last reported accounts showed losses of 74m, caused largely by write-offs of bad investments made by the previous directors.
Meldex floated on AIM in 2003 with a market capitalisation of 16m and reached a high of 150m to become the darling of the AIM market.
In 2005 the shares were the most traded on AIM. However, after a series of disastrous largely by write-offs of bad investments made by the previous directors.
Meldex floated on AIM in 2003 with a market capitalisation of 16m and reached a high of 150m to become the darling of the AIM market.
In 2005 the shares were the most traded on AIM. However, after a series of disastrous investments a new management team (including the return of Barry Muncaster) was bought in January 2009 to try and turn the companys fortunes around.
Having spent a few months restructuring the business, new funds were introduced from existing shareholders and creditors in September 2009.
Mr Muncaster said: What we found on our arrival was quite a shock. The actions of the previous directors left the company little choice but to pursue them through the courts. This proved to be a highly costly action. Recently, previously unknown liabilities have resulted in the company no longer being able to meet its debts. For those who put new money into the company last year under a fresh issue of loan notes, there is some hope. The money advanced was secured over the assets of the company and any sale of the subsidiary should result in funds being returned to the loan note holders.
Mr McKay said: There is a lesson here for all investors. If you need to put new money into a business to keep it afloat, try to secure the debt against some assets. It wont guarantee that you will get your money back but it certainly moves you up the creditors list.
Any interested parties or investors should contact the joint administrators immediately, he said.
Meldex, via BioProgress Technology, is involved in developing non-gelatin edible films for the pharmaceutical, healthcare and recreational industries in other words, pill-coatings for vegetarians.

"... in other words, pill-coatings for vegetarians"


A world beater lol

what a mess but i bet somone has done very well out of it

Two ?

Just popped by for a laugh. ;-))

Why do people believe things a BoD says. Rule 1 is that they always talk it up. If you can't get to grips with that then stay out of the markets.